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The pneumococcal phosphorylcholine esterase (Pce or CbpE) is a modular
protein that hydrolyses the phosphorylcholine residues present in the teichoic
and lipoteichoic acids of the pneumococcal cell wall. Pce has been crystallized
using the hanging-drop vapour-diffusion method at 291 K. Diffraction-quality
monoclinic crystals belong to space group C2, with unit-cell parameters
a = 169.82, b = 57.26, c = 67.44 AÊ ,  = 112.60. A 2.7 AÊ resolution SAD data set
from a non-isomorphous Gd-HPDO3A Pce derivative was collected at the
gadolinium LIII absorption edge using synchrotron radiation.
1. Introduction
Streptococcus pneumoniae is the major human Gram-positive
pathogen. Many interactions with the host are mediated speci®cally
by the phosphorylcholine residues present in the teichoic and lipo-
teichoic acids of the cell wall. These residues are recognized by
components of the host response (Cundell et al., 1995; Pepis &
Hirsch®eld, 2003) and serve as anchors for many surface-located
proteins (Yother et al., 1992; Yother & White, 1994; LoÂ pez & GarcõÂa,
2004 and references therein), including proteins involved in cell
adhesion and virulence (Yother et al., 1992; Hammerschmidt et al.,
1997; Rosenow et al., 1997; SaÂnchez-Beato et al., 1998; Brooks-Walter
et al., 1999). The biological role of choline during infection is a subject
of current interest and it has been suggested that bacteria with a
lower content of choline may escape the innate clearance mechanism
in the bloodstream (Yother et al., 1998; Weiser & Kapoor, 1999). The
pneumococcal pce gene encodes a teichoic acid phosphorylcholine
esterase (Pce or CbpE) that removes phosphorylcholine residues
from the cell-wall teichoic and lipoteichoic acids (de las Rivas et al.,
2001; Vollmer & Tomasz, 2001). Therefore, Pce activity remodels the
distribution of phosphorylcholine residues on the pneumococcal
envelope, modulating the activity of choline-dependent enzymes and
consequently the pathogen±host interactions. Pce carries an
N-terminal signal sequence of 25 amino acids. The mature form of the
protein (602 amino acids, 69 426 Da) contains a catalytic module
localized in the N-terminal part of the protein and a choline-binding
module at the C-terminal position that attaches the enzyme to the
bacterial cell wall (de las Rivas et al., 2001; Vollmer & Tomasz, 2001).
The sequence of the catalytic module reveals a low similarity with
enzymes of the /-metallohydrolase family of the -lactamase fold.
The choline-binding module contains ten homologous repeating units
of about 20 amino acids, similar to those found in other choline-
binding proteins (Pfam PF01473), and a long C-terminal tail of 85
residues that does not present any known similarity with sequences in
protein databases. Interestingly, a Pce mutant with signi®cantly
reduced colonization of the nasopharynx that was attributed to a
decreased ability to adhere to human cells has been reported (Gosink
et al., 2000) and Pce inactivation resulted in increased virulence in an
intraperitoneal inoculation model (Vollmer & Tomasz, 2001).
Therefore, it appears that solving the Pce structure may open new
therapeutic prospects for treating pneumococcal diseases. In this
communication, we present preliminary results obtained by X-ray
crystallography on the complete Streptococcus pneumoniae phos-
phorylcholine esterase.
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2. Experimental
2.1. Pce phosphorylcholinesterase production and purification
The pce truncated mutant (Pce55) was constructed by cloning
into plasmid pT7-7 (Tabor & Richardson, 1985) the PCR fragment
ampli®ed with the oligonucleotide 50-CCGAATTCAAGGAGATT-
AACATATGCAAGAAAGTTCAGGAAATAAAATCC-30 (where
the NdeI restriction site is underlined and the start codon is in bold),
complementary to the 50 end of the signal peptide of the pce gene (50-
CCGAATTCAAGGAGATTAACATATGCAAGAAAGTTCAGG-
AAATAAAATCC-30) and with the oligonucleotide 50-CGGGAT-
CCTCATTATGTAGTTTTAATTGTAGCAGATTTCTC-30 (where
the BamHI restriction site is underlined and the complementary stop
codon is in bold) complementary to the 30 end of the deletion site
(50-CGGGATCCTCATTATGTAGTTTTAATTGTAGCAGATTTC-
TC-30). The restriction sites were NdeI and BamHI. The recombinant
strain culture was expressed using 50 mM isopropylthio--d-galacto-
pyranoside as inducer in Escherichia coli strain BL21 (DE3). The
DNA sequence of the pce mutant was con®rmed with an automated
Abi Prism 3700 DNA sequencer (Applied Biosystems). All primers
were synthesized on a Beckman Oligo 1000M synthesizer. Restriction
enzymes and other DNA-modifying enzymes were purchased from
Amersham. Pce phosphorylcholine esterase and its truncated form
were puri®ed from cell extracts of E. coli BL21 (DE3) (pRGR12) or
E. coli BL21 (DE3) (pAPM01), respectively, by af®nity chromato-
graphy on DEAE cellulose equilibrated with phosphate/Zn buffer
(20 mM sodium phosphate, 3 mM ZnCO3 pH 7.0) following the
general procedure described by SaÂnchez-Puelles et al. (1990). The
protein was speci®cally eluted using a linear gradient (0±70 mM
choline in 2 h; elution rate 1 ml minÿ1) in phosphate/Zn buffer with
0.05 M NaCl. The homogeneity of the protein preparations was
con®rmed by SDS±PAGE and mass spectrometry. Pce activity was
assayed at 298 K using p-nitrophenylphosphorycholine (NPPC) as
substrate by measuring the absorbance of the product, p-nitrophenol,
at 410 nm (de las Rivas et al., 2001). Fractions with high purity and
activity were pooled and extensively dialyzed against Tris/Zn buffer
(50 mM Tris±HCl, 3 mM ZnCO3 pH 8.0) in the absence and presence
of 10 mM choline. The enzyme was then concentrated at 277 K with a
10 kDa cutoff protein concentrator (Amicon, YM-10) to approxi-
mately 11 mg mlÿ1. The ®nal protein concentration was determined
by spectrophotometry assuming a molar absorption coef®cient of
194 020 Mÿ1 cmÿ1 at 280 nm.
2.2. Mass spectrometry
MALDI±TOF measurements were performed using a Voyager
DE-PRO mass spectrometer from Applied Biosystems equipped with
a pulsed nitrogen laser ( = 337 nm, 10 ns pulse width, 3 Hz
frequency) and a delayed extraction ion source. Ions generated by the
laser desorption were introduced into the ¯ight tube (1.3 m ¯ight
path) with an acceleration voltage of 25 kV in the linear positive-ion
mode. All mass spectra were collected by averaging the signals of 500
laser shots.
2.3. N-terminal sequencing
The N-terminal sequence of Pce and its proteolytic fragments was
determined as described by Speicher (1994) using an automatic
sequencer (model 477A from Applied Biosystems).
2.4. Crystallization
The initial crystallization conditions were established utilizing the
sparse-matrix sampling technique (Jancarik & Kim, 1991) and the
hanging-drop vapour-diffusion method at 291 K using Index Screens I
and II from Hampton Research. Each hanging drop, made by mixing
1 ml protein solution and 1 ml well solution, was equilibrated against
500 ml well solution. With Pce that has been dialyzed in the presence
of 10 mM choline, plate-shaped crystals were obtained in condition
No. 45 of Index Screen I (0.1 M Tris pH 8.5, 25% PEG 3350). The
crystals were systematically twinned thin plates that only diffracted to
3 AÊ resolution. In order to improve the crystallization process, the
last 55 amino acids were deleted. The activity of the truncated form
(Pce55) was similar to that of the wild-type protein. The initial
conditions and all screens from Hampton Research were tested with
the truncated form. In the absence of choline, Pce55 crystallized in
the form of rods (Fig. 1a) under condition No. 65 of Index Screen II
(0.1 M bis-Tris pH 5.5, 0.1 M ammonium acetate, 17% PEG 10K) but
the crystals diffracted very poorly. Of 72 detergents and additives
tested with this condition (Detergent Screens 1, 2 and 3 and Additive
Screens 1, 2 and 3 from Hampton Research), only n-dodecyl phos-
phocholine 12 (Detergent Screen 3) produced a new crystal form
(Fig. 1b). The initial drop composition with which the best crystals
were obtained was 4 ml reservoir solution (17% PEG 10 000, 0.1 M
bis-Tris pH 5.5 and 0.1 M ammonium acetate), 1 ml 1.5 mM
n-dodecylphosphorylcholine and 4 ml protein solution. At 293 K,
crystals reached maximum dimensions of 0.1  0.3  0.3 mm in
15±30 d.
2.5. X-ray diffraction experiments
Diffraction data were collected from the native protein in-house on
a MAR 345 image-plate detector with Cu K X-rays generated by an
Enraf±Nonius rotating-anode generator equipped with a double-
mirror focusing system and operated at 40 kV and 90 mA. Crystals
were cryoprotected by a quick soak (10 s) in reservoir solution
containing in addition 30%(v/v) glycerol.
A non-isomorphous Gd derivative was obtained by soaking the
crystal for 1 min in mother liquor with 10 mM of the neutral gado-
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Figure 1
Effect of n-dodecylphosphocholine detergent on Pce crystals. (a) Crystals grown at
291 K in 0.1 M bis-Tris pH 5.5, 0.1 M ammonium acetate, 17% PEG 10K. (b)
Crystals obtained under the same conditions of precipitant and buffer but with
addition of 1.5 mM n-dodecylphosphocholine.
linium complex Gd-HPDO3A (Girard et al., 2003). The optimal
wavelength for data collection was taken at the white line ( =
1.7110 AÊ ) of the LIII absorption edge of Gd as determined from an
X-ray ¯uorescence spectrum collected on the soaked crystal. A SAD
data set was collected at 100 K using a CCD detector on beamline
BM30A at the European Synchrotron Radiation Facility (ESRF).
The crystal-to-detector distance was set to 110 mm. All data were
processed and scaled using XDS (Kabsch, 1988) and SCALA from
the CCP4 package (Collaborative Computational Project, Number 4,
1994). Data-collection statistics for the Gd-HPDO3A derivative of
Pce are summarized in Table 1.
3. Results and discussion
The ®rst crystals of native Pce showed serious twinning problems.
Careful analysis of protein stocks by SDS±PAGE and mass spectro-
metry showed the time-dependent appearance of two protein species
corresponding to truncated forms of Pce (66.9 and 63.5 kDa)
degraded at their C-terminal extreme, as con®rmed by N-terminal
sequence analysis. No further decrease in Pce molecular weight was
found in protein stocks after several months. Analysis of Pce crystals
by SDS±PAGE using silver staining showed that only the 63.5 kDa
species, which lacked the last 55 amino acids, crystallized. The
C-terminal region seems to be very ¯exible and no secondary-
structure element is predicted for it. Therefore, in order to improve
crystallization, the last 55 amino acids were deleted. The activity of
the truncated form (Pce55) was similar to that of the wild-type
protein. The best crystals of the truncated Pce form were obtained in
the presence of a speci®c detergent (n-dodecylphosphorylcholine).
They belong to the monoclinic space group C2, with unit-cell para-
meters a = 173.49, b = 58.12, c = 68.65 AÊ , = 108.29. Based on the Pce
molecular weight and on the unit-cell volume, the Matthews coef®-
cient of 4.0 AÊ 3 Daÿ1 (Matthews, 1968) suggests the presence of a
monomer in the asymmetric unit and a solvent content of 49%. Fast
crystallization communications
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Table 1
Data-collection statistics for the Pce Gd-HPDO3A-derivative crystal.
Values in parentheses refer to the highest resolution shell.
Crystal data
Space group C2
Unit-cell parameters
a (AÊ ) 169.82
b (AÊ ) 57.26
c (AÊ ) 67.44
 () 112.60
Data collection
Temperature (K) 100
Wavelength (AÊ ) 1.7110
Resolution (AÊ ) 43.85±2.68 (2.82±2.68)
Total re¯ections 58930
Unique re¯ections 16810
Redundancy 3.5 (2.2)
Completeness (%) 97.8 (85.4)
I/(I) 20.2 (5.0)
Rsym² 0.04 (0.28)
² Rsym =
P jI ÿ Iavj=P I, where the summation is over symmetry-equivalent
re¯ections.
Figure 2
X-ray diffraction pattern from a Pce crystal grown using the conditions described in
Fig. 1(b) (oscillation range 1). The edge of the plate corresponds to 1.9 AÊ
resolution.
Figure 3
(a) v = 0 Harker section and (b) v = 1/2 Harker section of the anomalous Patterson
map for the Gd-HPDO3A derivative. Levels are contoured in 1 steps starting at
2.
soaking in the presence of Gd-HPDO3A (Girard et al., 2003) led to
derivative crystals that produced a high-quality diffraction pattern to
2.68 AÊ resolution (Fig. 2). A total of 58 930 measured re¯ections were
merged into 16 810 unique re¯ections with an overall Rsym of 0.04. An
anomalous Patterson map was calculated using data in the entire
resolution range. The resulting v = 0 and v = 1/2 Harker sections are
shown in Fig. 3. Peaks corresponding to Gd-binding sites were clearly
observed in anomalous Patterson maps and four sites were located
using SHELX (Sheldrick, 1998). Initial phases were calculated at
2.68 AÊ resolution using the program SHARP (de La Fortelle
&Bricogne, 1997). Model building of the complete modular Pce is
currently in progress.
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